Quick Hits: 8 Portfolio Updates from Hydrogen to Healthcare

The portfolio is firing on multiple cylinders this month, with companies hitting significant inflection points from demonstration-scale manufacturing to coast-to-coast expansion. Here’s what’s moving:

Aduro

(Nasdaq: ADUR | CSE: ACT)

Aduro’s Letter of Intent for a Netherlands demonstration plant represents a masterclass in de-risking scale-up. By choosing a brownfield site for only $2m with existing infrastructure, they’re sidestepping the typical capital intensity trap that kills so many promising technologies at the demonstration phase.

The 25,000 tonnes per year potential full commercial capacity isn’t just a number, it’s the bridge between “interesting technology” and “investable business” for major industry players. The Netherlands location is particularly shrewd, positioning Aduro at the heart of Europe’s chemical recycling revolution where regulatory support meets actual market demand.

What strikes me most is the velocity. Moving from LOI to targeted closing in just a few months, with readiness for a demo plant by early 2027? That’s a management team that smells opportunity and is sprinting toward it. When companies move this fast on capital-intensive projects, it usually means the customer pull is real.

Watch the video for the full breakdown, but the takeaway is clear: Aduro is transitioning from technology developer to industrial operator. That’s where value creation accelerates.

Rocket Doctor AI: Building the Leadership Infrastructure for National Scale

This is disseminated by Rocket Doctor AI(US OTC: AIRDF | CSE: AIDR)

Rocket Doctor AI is making a statement with four strategic leadership hires that signal serious expansion ambitions:

• Dr. Evan Ou as U.S. Medical Director brings deep emergency medicine and digital health expertise.

• Dr. Sudha Kumar as U.S. MD Lead for Psychiatry strengthens behavioral health capabilities nationwide, with crucial insurance partnership experience.

• Dr. Mike Solemar as California MD Lead will drive recruitment and retention in one of the nation’s largest healthcare markets.

• Jimmy Vannavong as Director of Growth brings AI-powered digital marketing innovation to patient acquisition.

These aren’t just hires, they’re infrastructure for scale. Combined with new payer contracts and credentialing in New York and California, Rocket Doctor is methodically building the foundation for making healthcare more affordable and equitable for millions of Americans.

There has been so much progress here over the past few months, you can expect a full updated thesis from me in the next week or so.

LEEF Brands

(US OTC: LEEEF | CSE: LEEF)

LEEF Brands just delivered the breakout Q3 I’ve been promising. Revenue rose 24% year-over-year to $8.4 million, gross profit jumped 155% to $3.8 million, and margins doubled to 45%. For the first time, LEEF reported positive EBITDA ($735K) and operational cash flow ($350K), proving that vertical integration works.

In this exclusive Stock Therapy with Penny Queen interview, CEO Micah Anderson explains how LEEF’s 1,900-acre Salisbury Canyon Ranch in Santa Barbara County is transforming costs, how expansion into New York strengthens margins, and how federal rescheduling could reshape the entire cannabis sector.

CISO: Something Big Is Brewing

(NASDAQ: CISO)

CISO just requested to increase authorized shares from 300 million to 1.3 billion. When a company with 34.53 million shares outstanding makes a move like this, they’re not thinking incrementally.

The timing is intriguing: this comes alongside discussions about potentially bringing crypto into the treasury and securing crypto platforms. Whatever transformation they’re planning, the capital structure suggests it’s going to be significant. Watch this space.

South Pacific Resources: Drilling Into Value

(US OTC: SPMEF | TSX.v : SPMC)

Drilling is now underway at Osena (Ontenu NE), and I’ve just completed the first of three interviews with the executive chairman. This one is on their Kile Teke project.

Full disclosure: I’m extremely bullish and therefore biased here. Trading at $24 million USD when the underlying value could be closer to $150 million (my opinion) represents the kind of asymmetry that makes resource investing compelling. Yes, there’s risk, there always is with explorers but the risk/reward setup is particularly attractive.

Charbone: From Pennies to Production

(US OTC: CHHYF | TSX.v: CH)

Charbone has traveled quite a journey from our 5-cent financing with 5-cent warrants in January 2024. Now trading around 16 cents CAD, they’re approaching a critical inflection point: first hydrogen molecule production.

The $50 million USD non-dilutive credit facility changes the game entirely. This isn’t dilution, it’s expansion capital that should enable multiple clean hydrogen plants across North America. The addition of industry insider Patrick Cuddihy as Senior Vice President of Strategic Affairs signals they’re ready to navigate the complex hydrogen ecosystem at scale.

From a nickel to production-ready with non-dilutive growth capital, that’s execution.

Medicenna: The IL-2 Dark Horse

(US OTC: MDNAF | TSX: MDNA)

The IL-2 space just got an $11.5 billion validation stamp from a competitor deal, but Medicenna just played an even smarter card. They’ve partnered with Italy’s Fondazione Melanoma Onlus to launch NEO-CYT, a randomized neoadjuvant trial that could dramatically accelerate MDNA11’s path to market.

Here’s why this is brilliant: Instead of grinding through late-stage cancer patients with compromised immune systems, they’re moving upstream to earlier-stage melanoma where immune systems are intact and pathologic responses can be measured in weeks, not years. Major Pathologic Response (MPR) is considered predictive of long-term survival—meaning faster, clearer signals of efficacy.

The trial will test MDNA11 with nivolumab (anti-PD1) alone or with ipilimumab (anti-CTLA4). Professor Paolo Ascierto at one of Europe’s leading cancer centers is leading the charge. And here’s the kicker: Fondazione is sponsoring it, so Medicenna just supplies the drug—preserving their runway into mid-2026.

The stock has climbed to about $1.05 USD ahead of December’s ABILITY-1 data update at ESMO-IO. Between that readout and NEO-CYT results throughout 2026, we’ll have multiple catalysts to validate what I still believe is a superior IL-2 approach.

Sometimes the best moves aren’t the obvious ones. While others chase late-stage trials, Medicenna is building evidence where it matters most: earlier intervention with intact immune systems. I’m working to secure an interview to dig deeper into their differentiation story.

Liberty Stream Infrastructure Partners: Quick Win

(US OTC: VLTLF | TSX.v: LIB)Sometimes you catch lightning in a bottle. Liberty Stream Infrastructure Partners has delivered a solid double since I flagged it in late October, and the momentum suggests 2025 could be a banner year.

Not every investment needs to be a multi-year hold. Sometimes the market simply misprices an asset, and you take the gift. But I am seriously considering making this one part of my long-hold portfolio. It looks like

Across the portfolio, we’re seeing companies graduate from concept to commercial reality. Some are building hydrogen plants, others are transforming healthcare delivery, and a few are unlocking value that was hiding in plain sight.

The common thread? Execution. Ideas are cheap, execution creates value.

More updates as developments warrant.